Expands Nanox’s growing network of U.S. distribution partnerships
PETAH TIKVA, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Nano-X Imaging Ltd. (“Nanox”, or the “Company”, NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has signed a distribution agreement with Radiology Oncology Systems, a U.S. provider of diagnostic imaging and oncology equipment solutions serving hospitals and clinics nationwide, to distribute its Nanox.ARC systems across the U.S.
Under the terms of the agreement, Radiology Oncology Systems will support the commercial rollout of the Nanox.ARC, an FDA-cleared, multisource digital tomosynthesis system that makes 3D imaging possible in more clinical settings, at a lower cost and reduced radiation dose compared to traditional CT. Radiology Oncology Systems has a strong track record of supporting U.S. hospitals and clinics with reliable, cost-effective technologies designed to expand access to imaging and oncology-related clinical applications.
Through this collaboration, Nanox and Radiology Oncology Systems aim to broaden access to advanced imaging solutions across additional U.S. clinical settings, including oncology-adjacent care environments. The agreement includes the planned deployment of Nanox.ARC systems, leveraging Radiology Oncology Systems’ established distribution network and service infrastructure to support deployment.
“We continue to systematically expand our U.S. commercial footprint through targeted distribution agreements,” said Erez Meltzer, Chief Executive Officer and Acting Chairman of Nanox. “Radiology Oncology Systems adds another experienced partner to our growing U.S. network, bringing specialized expertise in oncology and diagnostic imaging that complements our existing channel partners and supports measured deployment and continued commercial execution.”
John Vano, President and Chief Executive Officer of Radiology Oncology Systems, said, “We are pleased to enter into this agreement with Nanox. We believe the Nanox.ARC aligns well with our focus on delivering practical, accessible imaging solutions to U.S. healthcare providers.”
This agreement represents another step in Nanox’s expanding U.S. distribution strategy, as the company continues to advance its channel partner strategy, building a diversified distribution network to support commercial deployment across the United States.
About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.
Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.
Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit www.nanox.vision.
About Radiology Oncology Systems (ROS)
For over 25 years, ROS has been providing affordable, high-quality, reconditioned radiation therapy and diagnostic imaging equipment solutions with proven end-to-end reliability. Solutions include refurbished Linear Accelerators (Linacs), CT scanners, MRI systems, PET/CT scanners, CT simulators, replacement parts, accessories, and related services for facilities around the world, increasing access to quality healthcare services for millions of patients.
Forward-Looking Statements
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xii) potential litigation associated with our transactions.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.
Contacts
Media Contact:
Ben Shannon
ICR Healthcare
[email protected]
Investor Contact:
Mike Cavanaugh
ICR Healthcare
[email protected]